According to a May 1, 2024 press release, the high-concentration (100 mg/mL), citrate-free formulation of Boehringer Ingelheim's Cyltezo® (adalimumab-adbm) was approved by the FDA on May 1 as interchangeable with AbbVie's Humira® (adalimumab)to treat multiple chronic inflammatory diseases. Cyltezo® was initially approved as a low-concentration biosimilar in August 2017 and as an interchangeable in October 2021. The low-concentration, citrate-free formulation of Cyltezo®has been available since July 1, 2023 at a 5-7% discount to Humira®, and a second unbranded version was launched in October 2023 at an 81% discount to Humira®. According to Boehringer Ingelheim the high-concentration Cyltezo®interchangeable will be available at the same discounts. Notably, the high-concentration adalimumab formulation accounts for about 80% of total Humira®prescriptions. This is the second FDA approval for a high-concentration interchangeable of Humira®, following Alvotech and Teva's Simlandi® (adalimumab-ryvk), which has yet to launch in the U.S.
According to a Samsung Bioepis report, the Humira® biosimilar market share was about 4% of the total adalimumab market as of February 2024. On April 1 it was reported that CVS Caremark dropped Humira®from some of its largest formularies which resulted in the adalimumab biosimilar market share increasing to about 36% of the total adalimumab market one week following the announcement.
Humira® had U.S. sales of nearly $12.2 billion in 2023.
For more information on this and other biosimilars, visit BiologicsHQ.
The authors would like to thank April Breyer Menon for her contributions to this article.
The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.